trial

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

NCTId NCT03356639
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 32 (actual)
Sponsored by Astellas Pharma Global Development, Inc.
Primary completion 2018-05-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2018-01-22
Primary completion
2018-05-30
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ASP6981

Sponsors

Astellas Pharma Global Development, Inc.Lead Sponsor

Investigators

1
Senior Medical DirectorStudy Director

Sites

2 total
Glendale, United StatesAustin, United States

Facts & assertions

4 sourced
Enrollment
32
Phase
PHASE1
Primary Completion Date
2018-05-30
Status
COMPLETED
relationships
The graph out of here
drug
ASP6981
drug
lead_sponsor
Astellas Pharma Global Development, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Senior Medical Director
person